Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | FABP7 | O15540 | 1/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.46 |
| ▸ | CPB1 | P15086 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16216073 | 1.00 | TSHR (0.52) | TSHRALDH1A1GAAHPGDSMN1; SMN2 | |
| SCHEMBL27100641 | 1.00 | TSHR (0.52) | TSHRALDH1A1GAAHPGDSMN1; SMN2 | |
| SCHEMBL10292295 | 1.00 | TSHR (0.52) | TSHRALDH1A1GAAHPGDSMN1; SMN2 | |
| SCHEMBL25635384 | 0.91 | TSHR (0.56) | TSHRALDH1A1GAAHPGDSMN1; SMN2 | |
| SCHEMBL25635382 | 0.91 | TSHR (0.56) | TSHRALDH1A1GAAHPGDSMN1; SMN2 | |
| SCHEMBL25635383 | 0.91 | TSHR (0.56) | TSHRALDH1A1GAAHPGDSMN1; SMN2 | |
| SCHEMBL14953736 | 0.91 | TSHR (0.55) | TSHRALDH1A1GAAHPGDSMN1; SMN2 | |
| SCHEMBL12035537 | 0.89 | ALDH1A1 (0.53) | TSHRALDH1A1GAAHPGDSMN1; SMN2 | |
| SCHEMBL11939907 | 0.89 | ALDH1A1 (0.53) | TSHRALDH1A1GAAHPGDSMN1; SMN2 | |
| SCHEMBL18717597 | 0.89 | ALDH1A1 (0.53) | TSHRALDH1A1GAAHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10781213-B2 | Methods for preparing bis-tetrahydroisoquinoline-containing compounds | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-09-22 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781213-B2 | Methods for preparing bis-tetrahydroisoquinoline-containing compounds | SYNCRIP, MYC, RPS27 | TSHR 2371/4885ALDH1A1 4005/4885GAA 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.